CALL - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Bid/Ask 08:28:54 2024-06-03 am EDT | ||
| 20.88 EUR / 20.89 EUR | +1.19% |
|
| 1 month | +3.98% | ||
| 3 months | +11.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 20.98 | +1.65% |
| 24-05-31 | 20.64 | -0.82% |
| 24-05-30 | 20.81 | +0.97% |
| 24-05-29 | 20.61 | -0.91% |
| 24-05-28 | 20.8 | -1.28% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 02:28 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VA9D9A |
| ISIN | DE000VA9D9A9 |
| Date issued | 2018-11-06 |
| Strike | 143 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.15 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
